

August 13, 2018

The Manager – Listing
BSE Limited,
1st Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai 400001

The Manager – Listing
National Stock Exchange of India Ltd.
Exchange plaza, 5th Floor, Plot No.C/1, G Block
Bandra-Kurla Complex, Bandra (E),
Mumbai 400051

Dear Sir(s),

Sub: Outcome of the Board Meeting held on Monday, August 13, 2018

Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN

At the Board Meeting of the Company held on Monday, August 13, 2018, the Board of Directors considered and approved the Unaudited Financial Results of the Company for the quarter ended June 30, 2018. The said Unaudited Financial Results together with the Limited Review report of the Statutory Auditors dated August 13, 2018 are enclosed herewith.

Please take the same on record.

Thanking you,

For AstraZeneca Pharma India Limited



Pratap Rudra
Company Secretary & Legal Counsel

AstraZeneca Pharma India Limited
 Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045
 Statement of unaudited financial results for the quarter ended 30 June 2018

SI No.	Particulars	Rs in lakhs except for earnings per share data			
		3 months ended 30/06/2018 (Unaudited)	3 months ended 31/03/2018 (Audited) Refer Note 7	3 months ended 30/06/2017 (Unaudited)	Year ended 31/03/2018 (Audited)
1	Revenue				
	a) Revenue from operations	16,143.68	15,072.66	12,846.58	57,198.92
	b) Other income (Refer Note 5)	342.28	233.82	465.41	1,224.76
	Total revenue	16,485.96	15,306.48	13,311.99	58,423.68
2	Expenses				
	(a) Cost of materials consumed	1,687.33	1,149.07	547.77	2,788.01
	(b) Purchase of stock-in-trade	1,999.45	2,472.62	5,843.96	20,421.17
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	1,648.04	783.69	(1,877.19)	(5,099.57)
	(d) Excise duty	-	-	98.50	98.50
	(e) Employee benefits expense	4,307.28	4,507.37	3,493.88	15,353.09
	(f) Depreciation and amortisation expense	355.04	355.08	370.80	1,473.75
	(g) Selling, marketing and distribution expense	2,862.02	2,111.30	1,185.91	7,280.51
	(h) Other expenses	2,711.61	2,521.67	2,932.06	11,728.21
	(i) Finance cost	-	-	-	-
	Total expenses	15,570.77	13,900.80	12,595.69	54,043.67
3	Profit before exceptional and extraordinary items and tax (1-2)	915.19	1,405.68	716.30	4,380.01
4	Exceptional items	-	-	-	-
5	Profit before extraordinary items and tax (3+4)	915.19	1,405.68	716.30	4,380.01
6	Extraordinary items	-	-	-	-
7	Profit before tax (5+6)	915.19	1,405.68	716.30	4,380.01
8	Tax expense				
	- Current tax	263.47	194.75	152.60	899.74
	- Deferred tax	12.38	888.79	(16.03)	888.79
	Total tax expense	275.85	1,083.54	136.57	1,788.53
9	Profit for the period (7-8)	639.34	322.14	579.73	2,591.48
10	Other comprehensive income, net of income tax				
	A. Items that will not be reclassified to profit or loss	166.51	(510.59)	62.36	(227.99)
	B. Items that will be reclassified to profit or loss	-	-	-	-
	Total other comprehensive income, net of income tax	166.51	(510.59)	62.36	(227.99)
	Total comprehensive income for the period (9+10)	805.85	(188.45)	642.09	2,363.49
11	Paid-up equity share capital (Face value of Rs 2/- per equity share)	500.00	500.00	500.00	500.00
12	Earnings per equity share of Rs 2/- each (basic and diluted)	2.56	1.29	2.32	10.37

Gagan



AstraZeneca Pharma India Limited

Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045

Statement of unaudited financial results for the quarter ended 30 June 2018

Notes:

- 1 The above statement of results has been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on 13 August 2018. The statutory auditors of the Company have carried out a limited review of this statement of results for the quarter ended 30 June 2018.
- 2 This Statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- 3 Ind AS 115 'Revenue from contracts with customers' mandatory for reporting periods beginning on or after 1 April 2018, replaces existing revenue recognition requirements. Under the modified retrospective approach, there were no significant adjustments required to the retained earnings as at 1 April 2018. The adoption of the standard did not have any impact on the financial results for the quarter.
- 4 The Company has identified 'Healthcare Segment' as its only reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly no segment information has been provided.
- 5 Other Income includes interest on income tax refund of Rs. 101.92 lakhs (3 months ended 30 June 2017: Rs. 268.26 lakhs).
- 6 As previously disclosed, by way a of letter dated 1 March 2014, AstraZeneca Pharmaceuticals AB, the promoter of the Company had proposed a voluntary delisting of the Company's equity shares from the National Stock Exchange and the Bombay Stock Exchange. Such proposed delisting is subject to an on-going inquiry with SEBI and that inquiry has not yet been resolved. In any event, based on the passage of time, any potential future proposal for voluntary delisting of the Company would need to be conducted de novo.
- 7 Figures for the quarter ended 31 March 2018 are the balancing figures between audited figures in respect of the full financial year ended 31 March 2018 and the published year to date figures up to the third quarter of the relevant financial year i.e 31 December 2017, which were subjected to review.
- 8 Previous period's figures have been regrouped, where necessary, to conform with the current period's presentation for the purpose of comparability.

By Order of the Board of Directors
For AstraZeneca Pharma India Limited

Place: Bengaluru
Date: 13 August 2018



Gagan Singh Bedi
Managing Director

Price Waterhouse & Co Chartered Accountants LLP

The Board of Directors
AstraZeneca Pharma India Limited
Block N1, 12th Floor,
Manyata Embassy Business Park,
Rachenahalli, Outer Ring Road,
Bengaluru 560045

1. We have reviewed the unaudited financial results of AstraZeneca Pharma India Limited (the "Company") for the quarter ended June 30, 2018 which are included in the accompanying 'Statement of unaudited financial results for quarter ended June 30, 2018' together with the notes thereon (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations, 2015"), which has been initialled by us for identification purposes. The Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Price Waterhouse & Co Chartered Accountants LLP
Firm Registration Number: 304026E/ E-300009



Pradip Kanakia
Partner
Membership Number: 039985

Place: Bengaluru
Date: August 13, 2018

*Price Waterhouse & Co Chartered Accountants LLP, 5th Floor, Tower 'D', The Millenia, 1 & 2 Murphy Road
Ulsoor, Bangalore-560 008
T: +91 (80) 4079 5000, F: +91 (80) 4079 5222*

Registered office and Head office: Plot No. Y-14, Block EP, Sector V, Salt Lake Electronic Complex, Bidhan Nagar, Kolkata 700 091

Price Waterhouse & Co. (a Partnership Firm) converted into Price Waterhouse & Co Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-4362) with effect from July 7, 2014. Post its conversion to Price Waterhouse & Co Chartered Accountants LLP, its ICAI registration number is 304026E/E-300009 (ICAI registration number before conversion was 304026E)